P

Periman Eye Institute | Seattle, WA

Research site
(Unclaimed)
Location
320 West Galer Street, Suite 201, Seattle, Washington, United States of America
Site insights

Top conditions

Keratoconjunctivitis Sicca (3 trials)

Dry Eye Syndromes (3 trials)

Eye Diseases (1 trial)

Meibomian Gland Dysfunction (1 trial)

Blepharitis (1 trial)

Top treatments

AR-15512
SAF312
Dupilumab
TP-03

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 6
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 (COMET-4)

This will be a 12-month, multicenter, vehicle-controlled, double-masked, randomized Phase 3 study conducted at approximately 10 sites in the United S...

Active, not recruiting
Dry Eye Disease
Drug: AR-15512 Ophthalmic Solution
Drug: Vehicle

To evaluate dry eye symptoms and contact lens wearing times after a single iLux treatment by evaluating change from baseline in OSDI scores, subjecti...

Enrolling
Dry Eye
Meibomian Gland Dysfunction
Procedure: Systane iLux thermal pulsation treatment

This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the effica...

Enrolling
Atopic Keratoconjunctivitis
Drug: Dupilumab

iTEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed.

Enrolling
Dry Eye
Device: iTEAR100 treatment

Trial sponsors

Aerie Pharmaceuticals logo

Aerie Pharmaceuticals (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems